Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosutinib in Ph+ Leukemias
NCT00261846Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jan 2006
- Primary completion
- Sep 2009
- Modality
- Small Molecules
- Countries
- 27
01
Overview
Phase 2, open-label, single-arm trial of bosutinib in chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), sponsored by Pfizer. Primary endpoints: Dose Limiting Toxicity at Day 28, Maximum Tolerated Dose at Day 28 and 4 more. Started Jan 2006; status: completed.
02
Drugs
bosutinib
03
Conditions
chronic myeloid leukemia (CML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00261846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00261846.